Clicky

Agenda

Date 1: 3 October 2022★

08:00 – 09:00 Scientific Session E: Immunobiology: Novel Findings in Infectious Diseases
 

Whole blood tests to measure T cell specific response in infectious diseases 

Prof. Delia Goletti 

National Institute for Infectious Diseases-IRCCS L. Spallanzani, Rome, Italy

09:00 – 10:00 Scientific Session B: New developments in Solid Tumors Immunotherapeutics
 

keynote Talk: Tumor associated Macrophages in Ovarian Cancer

Prof. Oliver Dorigo

Director, Division Gynecologic Oncology and

Director, Stanford Gynecologic Oncology Clinical Care Program

Stanford University, Stanford, US

10:00 – 11:00 Scientific Session C: New developments in Lung Cancers Diagnostics & Immunotherapeutics
 

Multiomics approaches to define actionable targets in malignant pleural mesothelioma

Prof. Cara Haymaker

UT MD Anderson Cancer Center, Houston, TX, USA

Immune Programs Associated to Tumoral Tertiary Lymphoid Structures at Different Maturation Stages in Early-stage Lung Adenocarcinoma

Dr Luisa M. Solis

Director of the Immunohistochemistry and Digital Pathology Laboratory & Department of Translational Molecular Pathology, MD Anderson Cancer Center, Houston, TX, USA

11:00 – 12:00 Scientific Session D: Immunobiology: Novel Scientific Developments & Clinical Applications
 

Bispecific fusion proteins: targeting tumor cells or immune cells

Prof. Yangxin Fu

Basic medical science, Tsinghua University, Beijing, China

12:00 – 13:00
Lunch Break
 

 

13:00 – 14:00 Scientific Session A: Immunobiology: Novel scientific Updates & Clinical Applications
 

Immunobiology personalized approaches in oncology.

Prof. Paolo Marchetti

Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS), Rome, Italy

14:00 – 15:00 Scientific Session F: Immunobiology: Novel scientific Developments & Clinical Applications
 

Development of targeted immunotherapy for HER2 tumors

Prof. Hongtao Zhang

Department of Pathology, Perelman School of Medicine, Philadelphia, USA

15:00 – 16:30 Scientific Session G: New Findings & Solutions: Infectious Diseases & Autoimmunity 
 

Targeting complement: from benchside to bedside

Prof. Panagiotis Skendros 

Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece

Complement Immunobiology

Dr Dimitrios C. Mastellos

National Center for Scientific Research ‘Demokritos’, Athens, Greece

Complement therapeutics in hematological disorders: lessons from PNH

Prof. Antonio Maria Risitano

AORN Moscati Avellino, Italy and Federico II University of Naples, Naples, Italy

Translating C3 inhibition in periodontal inflammation

Prof. George Hajishengallis

Department of Basic and Translational Sciences, University of Pennsylvania, Penn Dental Medicine, Philadelphia, USA.

16:30 – 17:30 Scientific Session H: New Findings in Infectious Diseases
 

T cell immune signatures triggered by Mycobacteria

Prof. Cecilia Lindestam Arlehamn

La Jolla Immunology Institute, San Diego, California USA

17:30 – 18:00 Scientific Session H: New Horizon in Autoimmune diseases
 

Expression of autoimmunity-related genes in melanoma

Dr Francesca Scatozza

Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS), Rome, Italy

Date 2: 4 October 2022★

08:00 – 09:00 Scientific Session A: New Horizon in Infectious Diseases Immunotherapeutics
 

Host directed therapies against mycobacterial infections

Prof. Giovanni Delogu

Università Cattolica del Sacro Cuore, Rome, Italy
09:00 – 10:00 Scientific Session B: New Findings & Solutions: Covid Immunotherapeutics
 

Cysteamine: a new therapy for SARS-CoV-2?

Dr Tonino Alonzi

National Institute for Infectious Diseases-IRCCS L. Spallanzani, Rome, Italy

10:00 – 11:00 Scientific Session C: New Horizon in Solid Tumors Immunotherapeutics
 

Arenavirus and odontogenic fibrous bone tumors: food-borne pathogens, eating habits and novel hypothesis

Dr Marco de Feo

Saint Mary’s Hospital Lacor, Gulu, Uganda

11:00 – 12:00 Scientific Session D: New Developments in Cancer Diagnostics & Therapeutics
 

Extracellular vesicle RNAs as diagnostics and future therapeutics in cancer

Dr Edgar Gonzalez-Kozlova

Department of Oncological Sciences, Icahn School of Medicine, New York, NY, USA

12:00 – 13:00 Lunch Break & Commercial Talk
  Commercial Talk

Severe Herpes Zoster Ophthalmicus: An Autobiographical Case Report

Dr Tibor Bakács

Hungarian Academy of Sciences & HepC Inc, Hungary

13:00 – 14:00 Scientific Session E: New Horizon in Covid Immunobiology
 

Myeloid derived Suppressor cells: key players in shaping the delicate balance between inflammation and immune-suppression in COVID-19 patients

Prof. Agrati Chiara

National Institute for Infectious Diseases-IRCCS L. Spallanzani, Rome, Italy

14:00 – 15:00 Scientific Session F: New Horizon in Breast Tumor Vaccines
 

Vaccines for breast cancer prevention

Prof. Disis, Mary L. (Nora)

Fred Hutchinson Cancer Research Center, WA, USA

15:00 – 16:00 Scientific Session G: New Findings & Solutions: Cancer Vaccines
 

Dendritic Cells: Cancer Vaccines , Modulators of TME and Inducers of T-cells for Adoptive T-cell Therapy

Prof. Pawel Kalinski

Jacobs Family Endowed Chair in Immunology, Roswell Park Comprehensive Cancer Center, Buffalo NY, USA

16:00 – 17:30 Scientific Satellite Symposium G: The role of chemotherapy in metastatic urothelial carcinoma (mUC); understanding cisplatin- and platinum-eligibility
 

Defining an ‘unfilt’ patient for Cisplatin-based chemo for the upfront treatment of metastatic urothelial carcinomas

Prof. Matthew Galsky

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, NY, USA

Defining platinum-ineligibility: I know it when I see it?

Dr Shilpa Gupta

Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, USA

A practical approach to selection of first-line treatment for metastatic urothelial cancer

Prof. Guru Sonpavde

Dana Farber Cancer Institute, Harvard Medical School, Boston, USA

Followed by:

Expert Panel Discussion and Questions & Answers

Date 3: 5 October 2022★

08:00 – 09:00 Scientific Session A: Immunobiology: Novel Scientific Developments & Clinical Applications
 

Engineering Bacterial Outer Membrane Vesicles for novel Immunotherapeutics

Prof. Viviana Izzo

Department of Medicine, Surgery and Dentistry, Università degli Studi Salerno, Baronissi (SA), Italy.

09:00 – 10:00 Scientific Session B: New Horizon in Solid Tumors Immunotherapeutics
 

Coupling vitiligo development and therapeutic efficacy: a new challenge for immunotherapy in cutaneous melanoma

Dr Cristina M. Failla

Experimental Immunology Laboratory, IDI-IRCCS, Rome, Italy

10:00 – 11:00 Scientific Session C: New Findings & Solutions: Covid, Infections
 

Future aspect of smart remote health monitoring in the midst of pandemic such as Covid

Prof. Chulho Oak

Kosin University College of Medicine, Pusan, South Korea

11:00 – 12:00 Scientific Session D: Modern Immuno-Diagnostics Techniques & Methods & Solutions
 

Immune diagnostic tests for Echinococcosis

Dr Linda Petrone

National Institute for Infectious Diseases-IRCCS L. Spallanzani, Rome, Italy

12:00 – 13:00
Lunch Break & Commercial Talk
  Commercial Talk

Network-Based Omics Approach Enables Precision Medicine Diagnostics and Drug Development

Jennifer N. Dines

Scipher Medicine Corp, Waltham, MA

13:00 – 14:00
Scientific Session E: New Developments in Infectious Diseases
 

Mycobacterial growth control in natural vs vaccine induced protection

Prof. Simone Joosten

Leiden, Medical Center, Leiden, The Netherlands

14:00 – 15:00 Scientific Session F: New developments in Solid Tumors Diagnostics & Immunotherapeutics
 

FOXP3 Instability and Treg cell-based therapy

Dr Bin Li

Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China

15:00 – 16:00 Scientific Session G: Scientific Session B: Immunotherapeutics in Infectious Diseases
 

Deep Spatial Profiling of the Tuberculosis Lung

Prof. Jyothi Rengarajan

Emory Vaccine Center Emory National Primate Center, Emory University, Atlanta, GA, USA

16:00 – 18:00 Scientific Satellite Symposium H: Emerging treatment options for metastatic hormone-sensitive prostate cancer (mHSPC); Understanding combination anti-androgen therapy and androgen deprivation therapy
 

Understanding the Genomic Landscape of Advanced Prostate Cancer

Prof. Che-Kai Tsao

 Medical Director, Ruttenberg Treatment Center, Tisch Cancer Institute, Mount Sinai Hospital, NY, USA.

Improving outcomes for patients with non-castrate (castration-sensitive) prostate cancer

Prof. Scott T. Tagawa

*Medical Director, Genitourinary Oncology Research Program, Weill Cornell Medical College, New York, USA

Treatment of Metastatic Castration Sensitive Prostate Cancer

Prof. Neeraj Agarwal

 Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah, Salt Lake City, UT, USA

Followed by:

Expert Panel Discussion and Questions & Answers

Conference End

★ Agenda is being updated regularly